Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Mark S. Sulkowski,Kosh Agarwal,Xiaoli Ma,Tuan T. Nguyen,Eugene R. Schiff,Hie-Won L. Hann,Douglas T. Dieterich,Ronald G. Nahass,James S. Park,Sing Chan,Steven-Huy B. Han,Edward J. Gane,Michael Bennett,Katia Alves, Marc Evanchik,Ran Yan,Qi Huang, Uri Lopatin,Richard Colonno,Julie Ma

Journal of Hepatology（2022）

引用 20|浏览34

暂无评分

摘要

•Complete suppression of HBV replication is essential for finite treatment regimens•Vebicorvir (VBR) is an HBV core protein inhibitor developed to treat chronic HBV•VBR interferes with 2 additional steps in HBV replication and thus complements NrtIs•VBR+ETV led to a significantly deeper reduction in HBV DNA and pregenomic RNA than ETV alone•VBR+ETV was associated with favorable safety and tolerability during 24 weeks of treatment

查看译文

关键词

Vebicorvir,ABI-H0731,core inhibitor,chronic hepatitis B virus,entecavir,nucleos(t)ide reverse transcriptase inhibitor,treatment-naïve,phase 2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要